Heat Biologics (HTBX) Q2 results:
Grant and licensing revenue: $0.6M (+100.0%).
Net loss: ($4.5M) (+6.3%); loss/share: ($0.05) (+64.3%).
The company has over $100M in cash and short-term investments as of August 6.
Heat Bio recently announced results from its COVID-19 vaccine candidate which showed encouraging action in pre-clinical study, validating that the selected vaccine antigen may be appropriate for human testing.
HTBX continue to accelerate PTX-35, a T-cell co-stimulatory antibody, through clinical development and announced patient enrollment in its first-in-human clinical trial in multiple solid tumors following FDA clearance of IND application.
“Additionally, we established a partnership with Waisman Biomanufacturing to manufacture our COVID-19 vaccine for anticipated Phase 1 trials in humans,” concluded Jeff Wolf, CEO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.